Bortezomib in Treating Patients With Lymphoproliferative Disorders

NCT00023764 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

NIH

Sponsor class

Conditions

Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

DRUG: bortezomib

Sponsor

National Cancer Institute (NCI)